[Therapeutic effect of carboplatin and etoposide combinative therapy on 123 lung cancer cases].
The clinical effect of Carboplatin and Etoposide (CE regimen) on 58 cases of small cell lung cancer (SCLC) and 65 cases of non small cell lung cancer (NSCLC) was observed, and its influence on immunity was investigated simultaneously. The result showed that the overall response rate of SCLC group was 72.4% (42/58). Among them, the response rate of primary treatment was 81.0% (31/38), and that of secondary treatment was 30.0% In NSCLC group, the response rate of primary treatment was 30.0% (6/20). In NSCLS group, the rate of primary treatment was 22.9% (8/35), and that of secondary treatment was 13.3% (4/30). From the result it was found that the response rate of primary treatment was higher than that of secondary treatment, and that the main side-effect of CE regimen was mild leukopenia, and the other side-effects included gastrointestinal symptoms, alopecia and mild hepatic function changes. The influence of CE regimen on immunity was temporary, and will soon recover. Repeating the regimen is reasonable. So we think that CE regimen is one of the best regimens for SCLC patients.
Shi
T Z
TZ
PLA General Hospital, Beijing.
Yan
J L
JL
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000276:immunology; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000276:immunology; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D016176:T-Lymphocyte Subsets / Q000187:drug effects
D005047:Etoposide; D016190:Carboplatin